MGI(SH:688114) Xin Lang Zheng Quan·2025-07-30 01:49Core Insights - The article highlights the successful application of BGI Genomics' sequencing technology in addressing the recent outbreak of Chikungunya virus in Guangdong Province, China, emphasizing the importance of rapid virus tracing and control measures [1][2][3] Group 1: Technology and Application - BGI Genomics' sequencing technology, particularly the DNBSEQ-T1+ and CycloneSEQ G100-ER platforms, plays a crucial role in virus genome sequencing and tracing, achieving over 99.9% coverage in the Chikungunya virus genome analysis [1] - The DNBSEQ-T1+ is noted for its ability to produce Tb-level data within 24 hours and can complete sequencing in as little as 7 hours, significantly enhancing the response efficiency to public health emergencies [1] - The CycloneSEQ platform, utilizing nanopore technology, provides real-time and portable sequencing capabilities, achieving 100% genome coverage in just 20 minutes, which aids in intercepting imported cases at customs [2] Group 2: Market Position and Growth - In 2024, 37 gene sequencing instruments received NMPA approval for clinical testing, with 23 of them based on BGI Genomics' DNBSEQ technology, representing 62% of the total approved devices in China [3] - BGI Genomics has sold over 4,500 sequencing instruments globally, capturing approximately 28.2% of the new sales market share, marking a significant increase of 9.5 percentage points from 2023 [3] - The company is expanding its business beyond core sequencing instruments to include biobanks, cell genomics, and spatial omics, while also exploring applications in judicial and animal disease fields [3] Group 3: Future Outlook - The growing demand across clinical, agricultural, disease control, and customs sectors, combined with the rapid growth of multi-omics business and increasing installation of core sequencing instruments, is expected to drive BGI Genomics' future performance [3] - As the only company globally with both large-scale commercial production of short-read (DNBSEQ) and long-read (CycloneSEQ) sequencing products, BGI Genomics is positioned to expand its market share and achieve steady performance growth [3]